ACM
BIIB icon

Avalon Capital Management’s Biogen BIIB Stock Holding History

Avalon Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,240
Closed -$919K – 82
2016
Q4 		$919K Sell
3,240
-60
-2% -$17.8K 0.7% 50
2016
Q3 		$1.03M Buy
+3,300
New +$977K 0.79% 37

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Avalon Capital Management's BIIB Position: Q1 2017 in Review

Avalon Capital Management sold out of Biogen (BIIB) in Q1 2017, closing a stake of 3,240 shares — an estimated $919K sold.

Avalon Capital Management first reported a position in BIIB in Q3 2016 and held it in 2 quarters. The position peaked at $1.03M in Q3 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • Avalon Capital Management reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • Avalon Capital Management sold 3,240 Biogen shares in Q1 2017, an estimated $919K.
  • Avalon Capital Management first reported a position in Biogen in Q3 2016 and held it in 2 quarters.
  • Avalon Capital Management's Biogen position peaked at $1.03M in Q3 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Avalon Capital Management's 13F filing for Q1 2017, filed 26 Apr 2017.